Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
Altimmune is one of several smaller biotech companies pushing to compete directly with Novo Nordisk and Eli Lilly in the growing weight loss drug space , or get scooped up by larger drugmakers that can help bring their treatments to market. The results are an early sign that the biotech company can address a major concern around those treatments, which have drawn unrelenting demand and investor interest over the last year. Some health experts have said that obesity drugs could shrink critical muscle mass, which could raise the risk of injuries and decrease strength. But more than 74% of the weight that patients lost after taking Altimmune's weekly injection came from fat tissue in the late-stage trial. Meanwhile, only 25.5% came from lean mass, according to the company. Those results are similar to those often seen with diet and exercise programs for weight loss. On average, patients lost 15.6% of their weight after taking a 2.4-milligram dose of Altimmune's medicine after 48
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy [Seeking Alpha]Seeking Alpha
- Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 [Yahoo! Finance]Yahoo! Finance
- Novo Reigns, Stellantis Resilient: EMEA Earnings Week Ahead [Yahoo! Finance]Yahoo! Finance
- Novo Reigns, Stellantis Resilient: EMEA Earnings Week Ahead [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Novo Reigns, Stellantis Resilient: EMEA Earnings Week Ahead [BNN Bloomberg (Canada)]BNN Bloomberg
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website